Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Panbela Therapeutics Inc PBLA

Healthcare Biotechnology
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI). Flynpovi is a combination of CPP-1X (eflornithine) and sulindac. It has a dual mechanism of action whereby it suppresses the synthesis of new polyamines and increases the export and catabolism of polyamines from the diet and microbiome. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes metastatic castration-resistant prostate cancer, and STK-11 mutant NSCLC.


OTCQB:PBLA - Post by User

Panbela Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(69)
•••
Post by Iseneschalon Apr 26, 2023 12:43pm
30 Views
Post# 35414877

PBLA ....some things never change

PBLA ....some things never changeMr. Maggot has his way with all the early a.m chasers....have u got this figured out yet???

This is a "train wreck"
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities